Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kirin Brewery Co. Ltd.

Division of Kirin Holdings Co. Ltd.
www.kirinholdings.co.jp/english/index.ht

Latest From Kirin Brewery Co. Ltd.

Argos Aims To Automate Cell-Based Cancer Therapy

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

BioPharmaceutical

The Rise Of Japanese Pharma Dealmakers

Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
BioPharmaceutical Middle East and Africa

The Next-Generation Antibody Players

A host of companies are vying to develop new and improved antibodies. Technologies span the gamut from improving ADCC effector function to stripping away components of traditional antibodies to create leaner molecules that may be cheaper to manufacture and eaiser to deliver orally. These start-ups remain product focused, eschewing the platform technology model. Pharmaceutical and established biotechnology companies are eager to get their hands on the technologies, causing a flurry of deal-making in the last year.
BioPharmaceutical Strategy

Anosys Inc.

As a former head of discovery research at Rhone-Poulenc Rorer Inc. (now Aventis SA), Jean-Bernard Le Pecq, PhD was accustomed to learning of new discoveries on a regular basis. But in 1997, one particular breakthrough in cell-to-cell communications caught his attention. Researchers found that small vesicles, known as exosomes, allow for the transfer of proteins to other cells. Le Pecq believed that exosomes could be used as a mechanism to develop innovative therapeutic vaccines and this idea ultimately propelled him to co-found Anosys Inc. in 1997.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Kirin Holdings Co. Ltd.
  • Senior Management
  • Kazuyasu Kato, Pres. & CEO
  • Contact Info
  • Kirin Brewery Co. Ltd.
    Phone: (81) 33 48 56 207
    10-1 Shinkawa 2-Chome
    Tokyo, 150
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register